Insights from the ISPOR Panel on the European Health Data Space

By João L. Carapinha

November 13, 2023

The European Health Data Space (EHDS) represents a groundbreaking initiative by the European Commission, poised to advance healthcare data management across the EU. As discussed in the recent ISPOR Europe conference panel, the EHDS is much more than a tool for pharmacovigilance and retrospective cohort studies.

It’s a comprehensive framework designed to empower EU citizens with equitable access to healthcare data while ensuring data privacy and fostering participation in intellectual property creation.

The EHDS is set to enhance the digitalization of health records and propel research. It supports the efficient utilization of electronic healthcare records and deployment of artificial intelligence for data analysis.

This advancement is not only expected to deepen research capabilities but also to spur innovation and improve policy-making at all societal levels.

Key opportunities presented by the EHDS include increased access to data and the attractiveness of Europe as a hub for clinical research, ultimately translating into improved patient outcomes. However, the implementation of the EHDS is not without challenges. These include ensuring transparency and trust in data sharing, addressing patient willingness to opt into data sharing, and navigating data protection and privacy concerns.

A significant challenge lies in extending the scope of EHDS beyond existing laws and regulations, aiming to build a stronger health data network backed by EU member states’ support.

Furthermore, panelists highlighted the importance of evaluating the readiness of EU member states to participate in the EHDS. Cultural barriers were identified as a critical hurdle, as the EHDS requires substantial organizational changes to facilitate the sharing, storage, and availability of data to various users and the research community.

As the EHDS progresses, it will undergo continuous improvement, driven by feedback from users and researchers accessing the data. This initiative is not just a standalone project but an integral component of the broader European Union. It aligns with the European strategy for data, indicating a holistic approach to data management and utilization across various sectors in the EU, with health data being a priority area.

In summary, the European Health Data Space is an ambitious and transformative project. It holds the promise of reshaping the landscape of healthcare research, policy-making, and industry practices within the EU, setting a precedent for the rest of the world in healthcare data management and utilization.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.